Friday, 11 September 2026

Indian corporate news, decoded into deal flow

NSE LIVE
NIFTY 50 INDIA VIX
as of
MARKETS
DEAL FLOW
Vijaya Diagnostic Acquires Arya Wellness Centre… ▲ Mergers & Acquisitions Indiabulls to Acquire 70% Stake in… ▲ Mergers & Acquisitions US CPI Data August 2026: Inflation… ▲ Global TVS Motor Expands Apache Portfolio in… ▲ Capex & Future Plan Raymond Aerospace Subsidiary Wins ₹33 Crore… ▲ Order Book Greenply Restructures JV: Samet to Invest… ▲ Corporate Actions Bharat Forge Simplifies German Subsidiary Structure… ▲ Mergers & Acquisitions
Home / Mergers & Acquisitions / Vijaya Diagnostic Acquires Arya Wellness Centre for ₹46 Crore, Enters Assam Market
MA · Mergers & Acquisitions

Vijaya Diagnostic Acquires Arya Wellness Centre for ₹46 Crore, Enters Assam Market

Vijaya Diagnostic Acquires Arya Wellness Centre for ₹46 Crore, Enters Assam Market

Vijaya Diagnostic Centre Limited is making a strategic entry into Assam with the 100% acquisition of Arya Wellness Centre, Guwahati, for approximately ₹46 crore.

The acquisition has been executed through a Business Transfer Agreement (BTA) with NEMRIL HRPL JV on a slump-sale basis and marks Vijaya Diagnostic’s entry into the North-East India diagnostics market.

The transaction is expected to close within approximately three months, subject to customary conditions precedent and other terms of the agreement.

₹46 Crore Acquisition Gives Vijaya Entry into Assam

Vijaya Diagnostic will acquire 100% of the integrated diagnostic business undertaking of Arya Wellness Centre in Guwahati.

The centre is located on GS Road, one of Guwahati’s prominent healthcare locations, and is surrounded by several leading hospitals.

For Vijaya, the acquisition provides an established operating platform in Guwahati rather than requiring the company to build a new centre from scratch.

Arya Wellness Centre Reported ₹26 Crore Revenue in FY26

Arya Wellness Centre is a B2C-focused integrated diagnostic centre established in 2021.

The business reported approximately:

  • FY26 Revenue: ₹26 crore
  • FY26 IND AS EBITDA: ₹5.6 crore
  • FY26 Adjusted PAT: ₹2.5 crore
  • B2C revenue contribution: More than 85%
  • Pathology contribution: 56%
  • Radiology contribution: 44%

The centre operates as a single-location business but has developed a strong B2C customer base.

Its diagnostic portfolio includes both pathology and radiology services.

Comprehensive Diagnostic Services Under One Roof

Arya Wellness Centre offers a broad range of diagnostic services, including:

  • MRI
  • CT scans
  • Ultrasound
  • Mammography
  • X-ray
  • Pathology tests
  • Histopathology
  • High-end interventional radiology procedures

This integrated service mix fits with Vijaya Diagnostic’s “All Under One Roof” operating model.

The company believes the combination of basic and advanced pathology and radiology services makes Arya Wellness Centre a strategically attractive asset.

Why Guwahati Is Important for Vijaya

The acquisition gives Vijaya its first operating presence in Assam and the North-East India market.

Guwahati is a major healthcare hub for Assam and the wider North-East. Patients from neighbouring districts and states travel to the city for advanced healthcare and diagnostic services.

Vijaya plans to use the Guwahati centre as a platform for potential expansion across Assam and the broader North-East region.

The move also extends the company’s existing geographic presence in West Bengal into a neighbouring region.

Management: Acquisition Expected to Be EPS Accretive

Vijaya’s management highlighted the financial discipline behind the transaction.

According to CFO Narasimha Raju KA, the deal has been concluded through a slump-sale structure at a valuation of approximately 8–9x FY26 IND AS EBITDA.

Importantly, the company expects the acquisition to be EPS accretive from the outset.

Management also said the transaction provides Vijaya with an established and profitable operating base in Guwahati while maintaining its focus on capital efficiency and return thresholds.

The company intends to continue evaluating both organic and inorganic expansion opportunities where there is a combination of strong market fundamentals, strategic fit, attractive valuations and healthy long-term returns on invested capital.

Vijaya Sees Further Expansion Opportunity in North-East

Managing Director and CEO Suprita Reddy said the Guwahati entry represents another milestone in Vijaya’s strategy of building a high-quality integrated diagnostics network.

The company believes Guwahati is a natural extension of its growing presence in West Bengal and could serve as a gateway to the North-East.

Management also highlighted Arya Wellness Centre’s B2C-focused model, advanced diagnostic capabilities and experienced clinical team as key reasons for the acquisition.

Focus Now on Integration and Patient Care

Vijaya’s immediate priority after completing the transaction will be to ensure a smooth transition.

The company plans to focus on:

  • Seamless integration of the acquired business
  • Strengthening the clinical and operating team
  • Maintaining continuity of patient care
  • Maintaining service quality
  • Leveraging Vijaya’s operating expertise and processes
  • Building the Guwahati platform for future regional expansion

Over time, Vijaya expects to use its existing capabilities to expand its presence across Assam and the wider North-East.

Acquisition at 8–9x EBITDA

At approximately ₹46 crore consideration against FY26 EBITDA of ₹5.6 crore, the transaction is being undertaken at roughly 8–9 times FY26 EBITDA, according to management.

The acquisition therefore appears focused on acquiring an already operating and profitable diagnostic centre rather than pursuing a high-cost greenfield expansion.

The expected EPS accretion will be an important factor for investors to monitor after the transaction closes.

Key Investor Takeaways

1. Entry into Assam:
Vijaya Diagnostic is entering the North-East diagnostics market through an established Guwahati centre.

2. ₹46 crore acquisition:
The company will acquire 100% of Arya Wellness Centre through a slump-sale transaction.

3. Profitable target:
Arya Wellness Centre generated ₹26 crore revenue, ₹5.6 crore EBITDA and ₹2.5 crore adjusted PAT in FY26.

4. Strong B2C business:
More than 85% of the centre’s revenue comes from the B2C segment.

5. Attractive valuation:
Management indicated a transaction valuation of approximately 8–9x FY26 IND AS EBITDA.

6. EPS accretive:
Vijaya expects the transaction to be EPS accretive from the outset.

7. Regional expansion opportunity:
Guwahati could become the company’s platform for further expansion across Assam and the North-East.

8. Near-term completion:
The acquisition is expected to close in approximately three months, subject to customary conditions.

What Investors Should Watch Next

The key factor will be how effectively Vijaya integrates Arya Wellness Centre and scales the business.

Investors should monitor:

  • Completion of the acquisition
  • Revenue growth at the Guwahati centre
  • EBITDA margins
  • B2C patient volumes
  • Utilisation of MRI, CT and other radiology assets
  • Expansion into other Assam locations
  • Further acquisitions in the North-East
  • Actual EPS impact after integration

Bottom Line

Vijaya Diagnostic’s ₹46 crore acquisition of Arya Wellness Centre is a strategically important expansion into Assam.

The deal combines an established B2C diagnostic business with ₹26 crore FY26 revenue and ₹5.6 crore EBITDA and gives Vijaya an operating foothold in Guwahati, a major healthcare hub for the North-East.

With management expecting the transaction to be EPS accretive from the outset and valuing the business at approximately 8–9x FY26 EBITDA, the acquisition could strengthen Vijaya’s long-term expansion strategy if the company successfully integrates the centre and replicates its model across the region.

Source: Vijaya Diagnostic Centre Limited disclosure and press release dated September 11, 2026.

Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors should independently evaluate the company’s financial performance, valuation, risks and future developments before making investment decisions.